WHO Greenlights LC16m8 Mpox Vaxx for Emergency Use
The World Health Organization (WHO) has granted Emergency Use Listing (EUL) for the LC16m8 mpox vaccine, marking it as the second mpox vaccine endorsed by the agency. This approval follows the declaration of mpox as a public health emergency of international concern (PHEIC) on 14 August 2024.
The decision is expected to enhance vaccine availability in regions experiencing surging mpox outbreaks, with 2024 reporting cases in 80 countries, including 19 in Africa. The Democratic Republic of the Congo, the most affected country, has recorded over 39,000 suspected cases and more than 1,000 deaths as of 31 October 2024.
Related: Asia Sees Rising Mpox Cases; Takes Action with Control and Treatment Measures
In a significant move, Japan announced a donation of 3.05 million doses of the LC16m8 vaccine, along with specialized needles, to Congo, marking the largest donation in response to the ongoing crisis.
Developed by KM Biologics in Japan, the LC16m8 vaccine is recommended for use in individuals over one year old in outbreak settings. It is administered as a single dose using a bifurcated needle. The vaccine has proven safe and effective, including for people with controlled HIV, though it is not recommended for pregnant individuals or those who are immunocompromised.
Related: Misconceptions on Mpox that You Should Know (and Public Perception in Malaysia)
WHO continues to collaborate with global partners to ensure the safe distribution of vaccines and ongoing research into their safety and effectiveness.
Category: Features, Pharmaceuticals
